glp-1 treatment for newly diagnosed diabetes guidelines The pharmacological management of Type 2 Diabetes, adapted from ADA 2025 guidelines, focusing on initiation and intensification based on patient comorbidities and glycemic control The New ADA/EASD Type 1

24 Furthermore, the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease trial, which involved participants with stage 2 to 4 CKD and moderately elevated albuminuria or stage 1 or 2 CKD and severely increased albuminuria, showed a reduction in CV morbidity, most prominently through a reduction in heart failure-related hospitalisations, with finerenone therapy

Patients reported that their daytime voiding frequency decreased from 9.5 times to 7.5 times per day, and nocturia (nighttime urination) resolved in 7 of 19 patients taking dulaglutide compared to only 1 of 16 patients on placebo

doi: 10.1210/jc.2015-2765 38 OuchiNWalshK

Advise against its use in patients with a hx of HTN See phentermine consent for additional details/medication packet regarding phentermine

Drucker DJ, Mojsov S, Habener JF

Compounded versions are legally and regulatorily distinct products